GenoLogics, a Victoria, British Columbia-based provider of laboratory information management system (LIMS) software specifically designed for next-generation genomics labs, raised $8m in funding.
The round was led by new investor Illumina, Inc., a provider of next-generation sequencing (NGS) instruments.
The company intends to use the funding to accelerate product development for future clinical applications and new desktop sequencing systems, as well as to expand sales and marketing functions.
In conjunction with the funding, Illumina Senior Vice President and CCO Tristan Orpin will join GenoLogics’ board of directors.
Led by CEO Michael Ball, the company provides laboratory information management system (LIMS) software specifically designed for next-generation genomics labs. Its GenoLogics LIMS delivers end-to-end management of genomics laboratory samples, tests and results.
Earlier this year, GenoLogics and Illumina already signed a worldwide co-selling agreement for the GenoLogics LIMS. The software, which was released in September, allows labs to move into production more quickly by incorporating de facto standards and best practices for NGS implementations.